{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:35:18Z","timestamp":1793932518284,"version":"4.8.0"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Progressive supranuclear palsy (PSP) is a rare and debilitating four-repeat (4R) tauopathy, characterized by motor dysfunction, cognitive decline, and oculomotor abnormalities, yet it lacks reliable biomarkers for early diagnosis, disease stratification, and prognosis. This review critically examines recent advancements in human biomarker research for PSP across multiple domains, including fluid specimen assays, i.e., blood and cerebrospinal fluid (CSF) assays, molecular profiling, and neuroimaging, with the aim of identifying markers that facilitate differential diagnosis, monitor disease progression, and support subtype classification. By synthesizing the findings of studies published, this article highlights the established biomarkers and emerging biomarkers from novel analytical methods and in vivo technologies and their potential utility for clinical trials. Emerging potential biomarkers considered include exosomal \u03b1-synuclein and tau aggregates, circulating molecular biomarkers, and relevant biomarkers from magnetic resonance spectroscopy (MRS), diffusion tensor imaging, neuromelanin MRI (NM-MRI), and functional MRI (fMRI) methods. Furthermore, the heterogeneous clinical presentations clearly reflect variable anatomical and molecular pathology in PSP and indicate that relying solely on clinical classification risks misdiagnosis, delayed treatment, and inappropriate management. A biologically grounded biotyping framework, which includes multimodal data integration and artificial intelligence, can resolve this heterogeneity by aligning observable phenotypes with underlying pathophysiology. To move beyond purely clinical classifications, this review proposes a conceptual biotyping framework to categorize PSP based on underlying biological processes, such as neurodegeneration, tau pathology, and neuroinflammation. This framework aims to guide future biomarker validation efforts, facilitate patient stratification in clinical trials, and accelerate the transition toward precision medicine approaches in PSP.<\/jats:p>","DOI":"10.1007\/s00415-025-13539-6","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:06:50Z","timestamp":1765951610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework"],"prefix":"10.1007","volume":"273","author":[{"given":"Christine","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5591-123X","authenticated-orcid":false,"given":"Teddy","family":"Salan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Pallikkuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-5194","authenticated-orcid":false,"given":"Varan","family":"Govind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"13539_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","volume":"10","author":"JC Steele","year":"1964","unstructured":"Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10:333\u2013359. https:\/\/doi.org\/10.1001\/archneur.1964.00460160003001","journal-title":"Arch Neurol"},{"issue":"3","key":"13539_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","volume":"8","author":"DR Williams","year":"2009","unstructured":"Williams DR, Lees AJ (2009) Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8(3):270\u2013279. https:\/\/doi.org\/10.1016\/S1474-4422(09)70042-0","journal-title":"Lancet Neurol"},{"issue":"14","key":"13539_CR3","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/mds.26054","volume":"29","author":"G Respondek","year":"2014","unstructured":"Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ et al (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29(14):1758\u20131766. https:\/\/doi.org\/10.1002\/mds.26054","journal-title":"Mov Disord"},{"issue":"1","key":"13539_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/wnl.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1\u20139. https:\/\/doi.org\/10.1212\/wnl.47.1.1","journal-title":"Neurology"},{"issue":"3","key":"13539_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","volume":"45","author":"DW Dickson","year":"2011","unstructured":"Dickson DW, Kouri N, Murray ME, Josephs KA (2011) Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci 45(3):384\u2013389. https:\/\/doi.org\/10.1007\/s12031-011-9589-0","journal-title":"J Mol Neurosci"},{"issue":"6","key":"13539_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853\u2013864. https:\/\/doi.org\/10.1002\/mds.26987","journal-title":"Mov Disord"},{"issue":"6","key":"13539_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/brain\/awh488","volume":"128","author":"DR Williams","year":"2005","unstructured":"Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L et al (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson\u2019s syndrome and PSP-parkinsonism. Brain 128(6):1247\u20131258. https:\/\/doi.org\/10.1093\/brain\/awh488","journal-title":"Brain"},{"issue":"4","key":"13539_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00002826-199308000-00006","volume":"16","author":"KA Nieforth","year":"1993","unstructured":"Nieforth KA, Golbe LI (1993) Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16(4):338\u2013346. https:\/\/doi.org\/10.1097\/00002826-199308000-00006","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"13539_CR9","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1002\/mds.20545","volume":"20","author":"AE Lang","year":"2005","unstructured":"Lang AE (2005) Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 20(12):S83-91. https:\/\/doi.org\/10.1002\/mds.20545","journal-title":"Mov Disord"},{"issue":"4","key":"13539_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"issue":"4","key":"13539_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jalz.2018.03.003","volume":"14","author":"AS Khachaturian","year":"2018","unstructured":"Khachaturian AS, Hayden KM, Mielke MM, Tang Y, Lutz MW, Gustafson DR et al (2018) Future prospects and challenges for Alzheimer\u2019s disease drug development in the era of the NIA-AA research framework. Alzheimers Dement 14(4):532\u2013534. https:\/\/doi.org\/10.1016\/j.jalz.2018.03.003","journal-title":"Alzheimers Dement"},{"issue":"7","key":"13539_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Hoglinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16(7):552\u2013563. https:\/\/doi.org\/10.1016\/S1474-4422(17)30157-6","journal-title":"Lancet Neurol"},{"key":"13539_CR13","doi-asserted-by":"publisher","first-page":"101644","DOI":"10.1016\/j.pneurobio.2019.101644","volume":"180","author":"TW Rosler","year":"2019","unstructured":"Rosler TW, Tayaranian Marvian A, Brendel M, Nykanen NP, Hollerhage M, Schwarz SC et al (2019) Four-repeat tauopathies. Prog Neurobiol 180:101644. https:\/\/doi.org\/10.1016\/j.pneurobio.2019.101644","journal-title":"Prog Neurobiol"},{"issue":"2","key":"13539_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3233\/JPD-140485","volume":"5","author":"J Rahimi","year":"2015","unstructured":"Rahimi J, Milenkovic I, Kovacs GG (2015) Patterns of tau and alpha-Synuclein pathology in the visual system. J Parkinsons Dis 5(2):333\u2013340. https:\/\/doi.org\/10.3233\/JPD-140485","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"13539_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/NEN.0000000000000030","volume":"73","author":"I Ferrer","year":"2014","unstructured":"Ferrer I, Lopez-Gonzalez I, Carmona M, Arregui L, Dalfo E, Torrejon-Escribano B et al (2014) Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. J Neuropathol Exp Neurol 73(1):81\u201397. https:\/\/doi.org\/10.1097\/NEN.0000000000000030","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"13539_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","volume":"140","author":"GG Kovacs","year":"2020","unstructured":"Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB et al (2020) Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol 140(2):99\u2013119. https:\/\/doi.org\/10.1007\/s00401-020-02158-2","journal-title":"Acta Neuropathol"},{"issue":"7","key":"13539_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ng.859","volume":"43","author":"GU Hoglinger","year":"2011","unstructured":"Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L et al (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43(7):699\u2013705. https:\/\/doi.org\/10.1038\/ng.859","journal-title":"Nat Genet"},{"issue":"4","key":"13539_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1750-3639.1999.tb00550.x","volume":"9","author":"L Buee","year":"1999","unstructured":"Buee L, Delacourte A (1999) Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick\u2019s disease. Brain Pathol 9(4):681\u2013693. https:\/\/doi.org\/10.1111\/j.1750-3639.1999.tb00550.x","journal-title":"Brain Pathol"},{"issue":"1","key":"13539_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1212\/01.wnl.0000191307.69661.c3","volume":"66","author":"KA Josephs","year":"2006","unstructured":"Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR et al (2006) Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 66(1):41\u201348. https:\/\/doi.org\/10.1212\/01.wnl.0000191307.69661.c3","journal-title":"Neurology"},{"issue":"7","key":"13539_CR20","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/mds.27038","volume":"32","author":"JL Whitwell","year":"2017","unstructured":"Whitwell JL, Hoglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C et al (2017) Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? Mov Disord 32(7):955\u2013971. https:\/\/doi.org\/10.1002\/mds.27038","journal-title":"Mov Disord"},{"issue":"6","key":"13539_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/mdc3.12995","volume":"7","author":"E Mulroy","year":"2020","unstructured":"Mulroy E, Jaunmuktane Z, Balint B, Erro R, Latorre A, Bhatia KP (2020) Some new and unexpected tauopathies in movement disorders. Mov Disord Clin Pract 7(6):616\u2013626. https:\/\/doi.org\/10.1002\/mdc3.12995","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"13539_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00401-013-1171-0","volume":"126","author":"Z Ahmed","year":"2013","unstructured":"Ahmed Z, Bigio EH, Budka H, Dickson DW, Ferrer I, Ghetti B et al (2013) Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol 126(4):537\u2013544. https:\/\/doi.org\/10.1007\/s00401-013-1171-0","journal-title":"Acta Neuropathol"},{"issue":"Pt 5","key":"13539_CR23","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/brain\/awn032","volume":"131","author":"KA Josephs","year":"2008","unstructured":"Josephs KA (2008) Neuropathological background of phenotypical variability in tauopathies. Brain 131(Pt 5):1362\u20131373. https:\/\/doi.org\/10.1093\/brain\/awn032","journal-title":"Brain"},{"issue":"5","key":"13539_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B et al (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80(5):496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1","journal-title":"Neurology"},{"key":"13539_CR25","doi-asserted-by":"publisher","first-page":"804385","DOI":"10.3389\/fnagi.2022.804385","volume":"14","author":"P Krzosek","year":"2022","unstructured":"Krzosek P, Madetko N, Migda A, Migda B, Jagus D, Alster P (2022) Differential diagnosis of rare subtypes of progressive supranuclear palsy and PSP-like syndromes-infrequent manifestations of the most common form of atypical parkinsonism. Front Aging Neurosci 14:804385. https:\/\/doi.org\/10.3389\/fnagi.2022.804385","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"13539_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/13554790590963004","volume":"11","author":"KA Josephs","year":"2005","unstructured":"Josephs KA, Boeve BF, Duffy JR, Smith GE, Knopman DS, Parisi JE et al (2005) Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 11(4):283\u2013296. https:\/\/doi.org\/10.1080\/13554790590963004","journal-title":"Neurocase"},{"issue":"6","key":"13539_CR27","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/WCO.0b013e3283168ddd","volume":"21","author":"KA Josephs","year":"2008","unstructured":"Josephs KA, Duffy JR (2008) Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol 21(6):688\u2013692. https:\/\/doi.org\/10.1097\/WCO.0b013e3283168ddd","journal-title":"Curr Opin Neurol"},{"key":"13539_CR28","doi-asserted-by":"publisher","first-page":"153331752092238","DOI":"10.1177\/1533317520922383","volume":"35","author":"S Pradhan","year":"2020","unstructured":"Pradhan S, Tandon R (2020) PSP-FTD complex: a possible variant of PSP. Am J Alzheimers Dis Other Demen 35:1533317520922383. https:\/\/doi.org\/10.1177\/1533317520922383","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"15","key":"13539_CR29","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/mds.21698","volume":"22","author":"DR Williams","year":"2007","unstructured":"Williams DR, Holton JL, Strand K, Revesz T, Lees AJ (2007) Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 22(15):2235\u20132241. https:\/\/doi.org\/10.1002\/mds.21698","journal-title":"Mov Disord"},{"issue":"5","key":"13539_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/mdc3.13489","volume":"9","author":"DMA Swallow","year":"2022","unstructured":"Swallow DMA, Zheng CS, Counsell CE (2022) Systematic review of prevalence studies of progressive supranuclear palsy and corticobasal syndrome. Mov Disord Clin Pract 9(5):604\u2013613. https:\/\/doi.org\/10.1002\/mdc3.13489","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"13539_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/aian.AIAN_611_20","volume":"24","author":"RR Mahale","year":"2021","unstructured":"Mahale RR, Krishnan S, Divya KP, Jisha VT, Kishore A (2021) Subtypes of PSP and prognosis: a retrospective analysis. Ann Indian Acad Neurol 24(1):56\u201362. https:\/\/doi.org\/10.4103\/aian.AIAN_611_20","journal-title":"Ann Indian Acad Neurol"},{"issue":"12","key":"13539_CR32","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.parkreldis.2013.07.019","volume":"19","author":"M Kanazawa","year":"2013","unstructured":"Kanazawa M, Tada M, Onodera O, Takahashi H, Nishizawa M, Shimohata T (2013) Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. Parkinsonism Relat Disord 19(12):1149\u20131151. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.07.019","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"13539_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.14802\/jmd.19061","volume":"13","author":"S Ando","year":"2020","unstructured":"Ando S, Kanazawa M, Onodera O (2020) Progressive supranuclear palsy with predominant cerebellar ataxia. J Mov Disord 13(1):20\u201326. https:\/\/doi.org\/10.14802\/jmd.19061","journal-title":"J Mov Disord"},{"issue":"9","key":"13539_CR34","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/mds.22583","volume":"24","author":"M Kanazawa","year":"2009","unstructured":"Kanazawa M, Shimohata T, Toyoshima Y, Tada M, Kakita A, Morita T et al (2009) Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study. Mov Disord 24(9):1312\u20131318. https:\/\/doi.org\/10.1002\/mds.22583","journal-title":"Mov Disord"},{"issue":"14","key":"13539_CR35","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/mds.26105","volume":"29","author":"AE Lang","year":"2014","unstructured":"Lang AE (2014) Clinical heterogeneity in progressive supranuclear palsy: challenges to diagnosis, pathogenesis and future therapies. Mov Disord 29(14):1707\u20131709. https:\/\/doi.org\/10.1002\/mds.26105","journal-title":"Mov Disord"},{"issue":"4","key":"13539_CR36","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/mds.28901","volume":"37","author":"RM Grijalva","year":"2022","unstructured":"Grijalva RM, Pham NTT, Huang Q, Martin PR, Ali F, Clark HM et al (2022) Brainstem biomarkers of clinical variant and pathology in progressive supranuclear palsy. Mov Disord 37(4):702\u2013712. https:\/\/doi.org\/10.1002\/mds.28901","journal-title":"Mov Disord"},{"key":"13539_CR37","unstructured":"Factor SA, Esper CD (2024) Progressive supranuclear palsy (PSP): Clinical features and diagnosis. UpToDate. https:\/\/www.uptodate.com\/contents\/progressive-supranuclear-palsy-psp-clinical-features-and-diagnosis. Accessed 8 Aug 2025"},{"issue":"1","key":"13539_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1\u20139. https:\/\/doi.org\/10.1212\/WNL.47.1.1","journal-title":"Neurology"},{"issue":"14","key":"13539_CR39","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/mds.26030","volume":"29","author":"G Respondek","year":"2014","unstructured":"Respondek G (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study. Mov Disord 29(14):1751\u20131760. https:\/\/doi.org\/10.1002\/mds.26030","journal-title":"Mov Disord"},{"key":"13539_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.parkreldis.2019.07.030","volume":"66","author":"L Marsili","year":"2019","unstructured":"Marsili L, Bologna M, Kojovic M, Berardelli A, Espay AJ, Colosimo C (2019) Dystonia in atypical parkinsonian disorders. Parkinsonism Relat Disord 66:25\u201333. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.030","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"13539_CR41","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00401-013-1090-8","volume":"125","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ (2013) Criteria for the diagnosis of corticobasal degeneration. Acta Neuropathol 125(5):621\u2013639. https:\/\/doi.org\/10.1007\/s00401-013-1090-8","journal-title":"Acta Neuropathol"},{"issue":"9","key":"13539_CR42","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/jnnp.2010.236588","volume":"82","author":"O Piguet","year":"2011","unstructured":"Piguet O (2011) Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. J Neurol Neurosurg Psychiatry 82(9):1027\u20131034. https:\/\/doi.org\/10.1136\/jnnp.2010.236588","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"13539_CR43","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/mds.27038","volume":"32","author":"JL Whitwell","year":"2017","unstructured":"Whitwell JL (2017) Imaging correlates of pathology in corticobasal syndrome and progressive supranuclear palsy. Mov Disord 32(7):955\u2013971. https:\/\/doi.org\/10.1002\/mds.27038","journal-title":"Mov Disord"},{"issue":"2","key":"13539_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/brain\/awab337","volume":"145","author":"JL Whitwell","year":"2022","unstructured":"Whitwell JL (2022) Neuroinflammation imaging in progressive supranuclear palsy using [11C]PK11195 PET. Brain 145(2):642\u2013657. https:\/\/doi.org\/10.1093\/brain\/awab337","journal-title":"Brain"},{"issue":"14","key":"13539_CR45","doi-asserted-by":"publisher","first-page":"e1367","DOI":"10.1212\/WNL.0000000000012639","volume":"97","author":"C Gaig","year":"2021","unstructured":"Gaig C, Compta Y, Heidbreder A, Marti MJ, Titulaer MJ, Crijnen Y et al (2021) Frequency and characterization of movement disorders in anti-IgLON5 disease. Neurology 97(14):e1367\u2013e1381. https:\/\/doi.org\/10.1212\/WNL.0000000000012639","journal-title":"Neurology"},{"key":"13539_CR46","doi-asserted-by":"publisher","first-page":"107289","DOI":"10.1016\/j.parkreldis.2025.107289","volume":"135","author":"Y Ono","year":"2025","unstructured":"Ono Y, Takigawa H, Takekoshi A, Yoshikura N, Aiba I, Hanajima R et al (2025) Frequency of anti-IgLON5 disease in patients with a typical clinical presentation of progressive supranuclear palsy\/corticobasal syndrome. Parkinsonism Relat Disord 135:107289. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107289","journal-title":"Parkinsonism Relat Disord"},{"key":"13539_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2020.08.013","volume":"79","author":"M Picillo","year":"2020","unstructured":"Picillo M, Amboni M, Bruni A, Maletta R, Barone P (2020) Prevalence of heterozygous mutations in Niemann-Pick type C genes in a cohort of progressive supranuclear palsy. Parkinsonism Relat Disord 79:9\u201310. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.08.013","journal-title":"Parkinsonism Relat Disord"},{"key":"13539_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147292","author":"L Marsili","year":"2021","unstructured":"Marsili L, Sharma J, Espay AJ, Migazzi A, Abdelghany E, Hill EJ et al (2021) Neither a novel tau proteinopathy nor an expansion of a phenotype: reappraising clinicopathology-based nosology. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22147292","journal-title":"Int J Mol Sci"},{"issue":"10","key":"13539_CR49","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1196","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J (2016) Comparison of Simoa and ELISA for neurofilament light chain quantification. Clin Chem Lab Med 54(10):1655\u20131664. https:\/\/doi.org\/10.1515\/cclm-2015-1196","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"13539_CR50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/acn3.290","volume":"3","author":"JC Rojas","year":"2016","unstructured":"Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V et al (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3(3):216\u2013225. https:\/\/doi.org\/10.1002\/acn3.290","journal-title":"Ann Clin Transl Neurol"},{"key":"13539_CR51","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.parkreldis.2018.06.018","volume":"56","author":"L Donker Kaat","year":"2018","unstructured":"Donker Kaat L, Meeter LH, Chiu WZ, Melhem S, Boon AJW, Blennow K et al (2018) Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat Disord 56:98\u2013101. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.06.018","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 6","key":"13539_CR52","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(Pt 6):1552\u20131565. https:\/\/doi.org\/10.1093\/brain\/awm032","journal-title":"Brain"},{"issue":"4","key":"13539_CR53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mds.29339","volume":"38","author":"SY Huang","year":"2023","unstructured":"Huang SY, Chen SF, Cui M, Zhao M, Shen XN, Guo Y et al (2023) Plasma biomarkers and positron emission tomography tau pathology in progressive supranuclear palsy. Mov Disord 38(4):676\u2013682. https:\/\/doi.org\/10.1002\/mds.29339","journal-title":"Mov Disord"},{"key":"13539_CR54","doi-asserted-by":"publisher","first-page":"119975","DOI":"10.1016\/j.cca.2024.119975","volume":"565","author":"Y Chen","year":"2025","unstructured":"Chen Y, Huang J, Li Y, Chen X, Ye Q (2025) Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson\u2019s disease. Clin Chim Acta 565:119975. https:\/\/doi.org\/10.1016\/j.cca.2024.119975","journal-title":"Clin Chim Acta"},{"key":"13539_CR55","doi-asserted-by":"publisher","first-page":"106978","DOI":"10.1016\/j.parkreldis.2024.106978","volume":"123","author":"MG Bianco","year":"2024","unstructured":"Bianco MG, Cristiani CM, Scaramuzzino L, Sarica A, Augimeri A, Chimento I et al (2024) Combined blood neurofilament light chain and third ventricle width to differentiate progressive supranuclear palsy from Parkinson\u2019s disease: a machine learning study. Parkinsonism Relat Disord 123:106978. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106978","journal-title":"Parkinsonism Relat Disord"},{"key":"13539_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612751","author":"X Capo","year":"2023","unstructured":"Capo X, Galmes-Panades AM, Navas-Enamorado C, Ortega-Moral A, Marin S, Cascante M et al (2023) Circulating neurofilament light chain levels increase with age and are associated with worse physical function and body composition in men but not in women. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241612751","journal-title":"Int J Mol Sci"},{"key":"13539_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00249-2","author":"T Chitnis","year":"2025","unstructured":"Chitnis T, Magliozzi R, Abdelhak A, Kuhle J, Leppert D, Bielekova B (2025) Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(25)00249-2","journal-title":"Lancet Neurol"},{"issue":"15","key":"13539_CR58","doi-asserted-by":"publisher","first-page":"e34720","DOI":"10.1016\/j.heliyon.2024.e34720","volume":"10","author":"Z Song","year":"2024","unstructured":"Song Z, Zhang S, Pan H, Hu B, Liu X, Cui J et al (2024) Global research trends on the links between NfL and neurological disorders: a bibliometric analysis and review. Heliyon 10(15):e34720. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34720","journal-title":"Heliyon"},{"issue":"5","key":"13539_CR59","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41582-025-01085-8","volume":"21","author":"L Kiani","year":"2025","unstructured":"Kiani L (2025) Neurofilament light chain induces neuroinflammation. Nat Rev Neurol 21(5):233. https:\/\/doi.org\/10.1038\/s41582-025-01085-8","journal-title":"Nat Rev Neurol"},{"key":"13539_CR60","doi-asserted-by":"publisher","first-page":"254248232513798","DOI":"10.1177\/25424823251379878","volume":"9","author":"K Thomas","year":"2025","unstructured":"Thomas K, Spin P, Sir N, Hou K, Ashton NJ, Zetterberg H et al (2025) Neurofilament light (NfL) chain levels predict clinical decline in Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis Rep 9:25424823251379880. https:\/\/doi.org\/10.1177\/25424823251379878","journal-title":"J Alzheimers Dis Rep"},{"issue":"1","key":"13539_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01093-6","volume":"14","author":"S Baiardi","year":"2022","unstructured":"Baiardi S, Quadalti C, Mammana A, Dellavalle S, Zenesini C, Sambati L et al (2022) Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther 14(1):153. https:\/\/doi.org\/10.1186\/s13195-022-01093-6","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"13539_CR62","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaneurol.2023.0488","volume":"80","author":"L VandeVrede","year":"2023","unstructured":"VandeVrede L, La Joie R, Thijssen EH, Asken BM, Vento SA, Tsuei T et al (2023) Evaluation of plasma phosphorylated Tau217 for differentiation between Alzheimer disease and frontotemporal lobar degeneration subtypes among patients with corticobasal syndrome. JAMA Neurol 80(5):495\u2013505. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0488","journal-title":"JAMA Neurol"},{"issue":"13","key":"13539_CR63","doi-asserted-by":"publisher","first-page":"6882","DOI":"10.3390\/ijms25136882","volume":"25","author":"CM Cristiani","year":"2024","unstructured":"Cristiani CM, Scaramuzzino L, Quattrone A, Parrotta EI, Cuda G, Quattrone A (2024) Serum oligomeric alpha-Synuclein and p-tau181 in progressive supranuclear palsy and Parkinson\u2019s disease. Int J Mol Sci 25(13):6882. https:\/\/doi.org\/10.3390\/ijms25136882","journal-title":"Int J Mol Sci"},{"issue":"6","key":"13539_CR64","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1111\/j.1471-4159.2008.05321.x","volume":"105","author":"S Wray","year":"2008","unstructured":"Wray S, Saxton M, Anderton BH, Hanger DP (2008) Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem 105(6):2343\u20132352. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05321.x","journal-title":"J Neurochem"},{"key":"13539_CR65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168553","author":"N Samudra","year":"2023","unstructured":"Samudra N, Lane-Donovan C, VandeVrede L, Boxer AL (2023) Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI168553","journal-title":"J Clin Invest"},{"key":"13539_CR66","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neurobiolaging.2021.08.011","volume":"108","author":"N Samimi","year":"2021","unstructured":"Samimi N, Sharma G, Kimura T, Matsubara T, Huo A, Chiba K et al (2021) Distinct phosphorylation profiles of tau in brains of patients with different tauopathies. Neurobiol Aging 108:72\u201379. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.08.011","journal-title":"Neurobiol Aging"},{"issue":"5","key":"13539_CR67","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s10072-019-04208-4","volume":"41","author":"I Inci","year":"2020","unstructured":"Inci I, Kusbeci OY, Eskut N (2020) The neutrophil-to-lymphocyte ratio as a marker of peripheral inflammation in progressive supranuclear palsy: a retrospective study. Neurol Sci 41(5):1233\u20131237. https:\/\/doi.org\/10.1007\/s10072-019-04208-4","journal-title":"Neurol Sci"},{"issue":"12","key":"13539_CR68","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1002\/mds.30009","volume":"39","author":"M Rosina","year":"2024","unstructured":"Rosina M, Veltri F, Nesci V, Bissacco J, Bovenzi R, Mascioli D et al (2024) Immunometabolic signature and tauopathy markers in blood cells of progressive supranuclear palsy. Mov Disord 39(12):2211\u20132219. https:\/\/doi.org\/10.1002\/mds.30009","journal-title":"Mov Disord"},{"issue":"1","key":"13539_CR69","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4049\/jimmunol.1801506","volume":"203","author":"CS Lindestam Arlehamn","year":"2019","unstructured":"Lindestam Arlehamn CS, Pham J, Alcalay RN, Frazier A, Shorr E, Carpenter C et al (2019) Widespread Tau-Specific CD4 T cell reactivity in the general population. J Immunol 203(1):84\u201392. https:\/\/doi.org\/10.4049\/jimmunol.1801506","journal-title":"J Immunol"},{"issue":"1","key":"13539_CR70","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41531-022-00282-2","volume":"8","author":"R Dhanwani","year":"2022","unstructured":"Dhanwani R, Lima-Junior JR, Sethi A, Pham J, Williams G, Frazier A et al (2022) Transcriptional analysis of peripheral memory T cells reveals Parkinson\u2019s disease-specific gene signatures. NPJ Parkinsons Dis 8(1):30. https:\/\/doi.org\/10.1038\/s41531-022-00282-2","journal-title":"NPJ Parkinsons Dis"},{"issue":"10","key":"13539_CR71","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/QAD.0000000000001821","volume":"32","author":"VK George","year":"2018","unstructured":"George VK, Pallikkuth S, Pahwa R, de Armas LR, Rinaldi S, Pan L et al (2018) Circulating inflammatory monocytes contribute to impaired influenza vaccine responses in HIV-infected participants. AIDS 32(10):1219\u20131228. https:\/\/doi.org\/10.1097\/QAD.0000000000001821","journal-title":"AIDS"},{"key":"13539_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314554","author":"FA Simoes","year":"2022","unstructured":"Simoes FA, Joilin G, Peters O, Schneider LS, Priller J, Spruth EJ et al (2022) Potential of non-coding RNA as biomarkers for progressive supranuclear palsy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232314554","journal-title":"Int J Mol Sci"},{"key":"13539_CR73","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.parkreldis.2021.11.020","volume":"93","author":"I Manna","year":"2021","unstructured":"Manna I, Quattrone A, De Benedittis S, Vescio B, Iaccino E, Quattrone A (2021) Exosomal miRNA as peripheral biomarkers in Parkinson\u2019s disease and progressive supranuclear palsy: a pilot study. Parkinsonism Relat Disord 93:77\u201384. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.11.020","journal-title":"Parkinsonism Relat Disord"},{"key":"13539_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58040483","author":"A Bougea","year":"2022","unstructured":"Bougea A (2022) MicroRNA as candidate biomarkers in atypical Parkinsonian syndromes: systematic literature review. Medicina Kaunas. https:\/\/doi.org\/10.3390\/medicina58040483","journal-title":"Medicina Kaunas"},{"issue":"2","key":"13539_CR75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W et al (2024) A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol 23(2):191\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(23)00404-0","journal-title":"Lancet Neurol"},{"issue":"4","key":"13539_CR76","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/hmg\/8.4.711","volume":"8","author":"M Baker","year":"1999","unstructured":"Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J et al (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8(4):711\u2013715. https:\/\/doi.org\/10.1093\/hmg\/8.4.711","journal-title":"Hum Mol Genet"},{"key":"13539_CR77","doi-asserted-by":"publisher","first-page":"7247","DOI":"10.1038\/ncomms8247","volume":"6","author":"N Kouri","year":"2015","unstructured":"Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A et al (2015) Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun 6:7247. https:\/\/doi.org\/10.1038\/ncomms8247","journal-title":"Nat Commun"},{"key":"13539_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/2051-5960-1-31","volume":"1","author":"LD Stutzbach","year":"2013","unstructured":"Stutzbach LD, Xie SX, Naj AC, Albin R, Gilman S, Group PSPGS et al (2013) The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer\u2019s disease. Acta Neuropathol Commun 1:31. https:\/\/doi.org\/10.1186\/2051-5960-1-31","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"13539_CR79","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-018-0267-3","volume":"13","author":"MY Sanchez-Contreras","year":"2018","unstructured":"Sanchez-Contreras MY, Kouri N, Cook CN, Serie DJ, Heckman MG, Finch NA et al (2018) Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener 13(1):37. https:\/\/doi.org\/10.1186\/s13024-018-0267-3","journal-title":"Mol Neurodegener"},{"issue":"4","key":"13539_CR80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41582-021-00463-8","volume":"17","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Blennow K (2021) Fluid biomarkers for neurodegenerative diseases: current state and future directions. Nat Rev Neurol 17(4):223\u2013234. https:\/\/doi.org\/10.1038\/s41582-021-00463-8","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"13539_CR81","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1212\/WNL.0000000000004859","volume":"90","author":"JC Rojas","year":"2018","unstructured":"Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL et al (2018) CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90(4):e273\u2013e281. https:\/\/doi.org\/10.1212\/WNL.0000000000004859","journal-title":"Neurology"},{"issue":"1","key":"13539_CR82","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.1038\/s41598-020-66090-x","volume":"10","author":"C Delaby","year":"2020","unstructured":"Delaby C, Alcolea D, Carmona-Iragui M, Illan-Gala I, Morenas-Rodriguez E, Barroeta I et al (2020) Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep 10(1):9161. https:\/\/doi.org\/10.1038\/s41598-020-66090-x","journal-title":"Sci Rep"},{"issue":"10","key":"13539_CR83","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jnnp-2017-315857","volume":"88","author":"E Jabbari","year":"2017","unstructured":"Jabbari E, Zetterberg H, Morris HR (2017) Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry 88(10):883\u2013888. https:\/\/doi.org\/10.1136\/jnnp-2017-315857","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"13539_CR84","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3233\/JAD-215616","volume":"87","author":"N Bendstrup","year":"2022","unstructured":"Bendstrup N, Hejl AM, Salvesen L (2022) Neurofilament light chain levels in frontotemporal dementia and progressive supranuclear palsy: a systematic review. J Alzheimers Dis 87(1):131\u2013140. https:\/\/doi.org\/10.3233\/JAD-215616","journal-title":"J Alzheimers Dis"},{"issue":"1\u20132","key":"13539_CR85","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2015.03.041","volume":"352","author":"W Sako","year":"2015","unstructured":"Sako W, Murakami N, Izumi Y, Kaji R (2015) Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson\u2019s disease from atypical parkinsonism: evidence from a meta-analysis. J Neurol Sci 352(1\u20132):84\u201387. https:\/\/doi.org\/10.1016\/j.jns.2015.03.041","journal-title":"J Neurol Sci"},{"issue":"1","key":"13539_CR86","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41531-021-00232-4","volume":"7","author":"C Quadalti","year":"2021","unstructured":"Quadalti C, Calandra-Buonaura G, Baiardi S, Mastrangelo A, Rossi M, Zenesini C et al (2021) Neurofilament light chain and alpha-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. NPJ Parkinsons Dis 7(1):93. https:\/\/doi.org\/10.1038\/s41531-021-00232-4","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"13539_CR87","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K et al (2015) A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 86(11):1240\u20131247. https:\/\/doi.org\/10.1136\/jnnp-2014-309562","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"13539_CR88","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/brain\/awab481","volume":"145","author":"A Snellman","year":"2022","unstructured":"Snellman A, Lantero-Rodriguez J, Emersic A, Vrillon A, Karikari TK, Ashton NJ et al (2022) N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain 145(8):2834\u20132848. https:\/\/doi.org\/10.1093\/brain\/awab481","journal-title":"Brain"},{"key":"13539_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081781","author":"N Giagkou","year":"2024","unstructured":"Giagkou N, Kapsali I, Brinia ME, Constantinides VC (2024) Cerebrospinal fluid total and phosphorylated tau protein in behavioral variant frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome and non-fluent agrammatic primary progressive aphasia: a systematic review and meta-analysis. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12081781","journal-title":"Biomedicines"},{"issue":"1","key":"13539_CR90","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12974-022-02640-6","volume":"19","author":"JD Cherry","year":"2022","unstructured":"Cherry JD, Baucom ZH, Eppich KG, Kirsch D, Dixon ER, Tripodis Y et al (2022) Neuroimmune proteins can differentiate between tauopathies. J Neuroinflammation 19(1):278. https:\/\/doi.org\/10.1186\/s12974-022-02640-6","journal-title":"J Neuroinflammation"},{"issue":"3","key":"13539_CR91","doi-asserted-by":"publisher","first-page":"e209585","DOI":"10.1212\/WNL.0000000000209585","volume":"103","author":"A Wise","year":"2024","unstructured":"Wise A, Li J, Yamakawa M, Loureiro J, Peterson B, Worringer K et al (2024) CSF proteomics in patients with progressive supranuclear palsy. Neurology 103(3):e209585. https:\/\/doi.org\/10.1212\/WNL.0000000000209585","journal-title":"Neurology"},{"key":"13539_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105947","volume":"176","author":"M Meloni","year":"2023","unstructured":"Meloni M, Agliardi C, Guerini FR, Zanzottera M, Bolognesi E, Picciolini S et al (2023) Oligomeric alpha-synuclein and tau aggregates in NDEVs differentiate Parkinson\u2019s disease from atypical parkinsonisms. Neurobiol Dis 176:105947. https:\/\/doi.org\/10.1016\/j.nbd.2022.105947","journal-title":"Neurobiol Dis"},{"issue":"11","key":"13539_CR93","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/mds.28639","volume":"36","author":"A Stuendl","year":"2021","unstructured":"Stuendl A, Kraus T, Chatterjee M, Zapke B, Sadowski B, Moebius W et al (2021) Alpha-synuclein in plasma-derived extracellular vesicles is a potential biomarker of Parkinson\u2019s disease. Mov Disord 36(11):2508\u20132518. https:\/\/doi.org\/10.1002\/mds.28639","journal-title":"Mov Disord"},{"issue":"20","key":"13539_CR94","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1212\/WNL.0b013e318292a2d2","volume":"80","author":"LA Massey","year":"2013","unstructured":"Massey LA, Jager HR, Paviour DC, O\u2019Sullivan SS, Ling H, Williams DR et al (2013) The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 80(20):1856\u20131861. https:\/\/doi.org\/10.1212\/WNL.0b013e318292a2d2","journal-title":"Neurology"},{"key":"13539_CR95","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2016.05.006","volume":"28","author":"E Owens","year":"2016","unstructured":"Owens E, Krecke K, Ahlskog JE, Fealey R, Hassan A, Josephs KA et al (2016) Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy. Parkinsonism Relat Disord 28:107\u2013111. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.05.006","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"13539_CR96","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1212\/WNL.0000000000003125","volume":"87","author":"A Quattrone","year":"2016","unstructured":"Quattrone A, Morelli M, Williams DR, Vescio B, Arabia G, Nigro S et al (2016) MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism. Neurology 87(12):1266\u20131273. https:\/\/doi.org\/10.1212\/WNL.0000000000003125","journal-title":"Neurology"},{"issue":"1","key":"13539_CR97","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1148\/radiol.2453061703","volume":"246","author":"A Quattrone","year":"2008","unstructured":"Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P et al (2008) MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 246(1):214\u2013221. https:\/\/doi.org\/10.1148\/radiol.2453061703","journal-title":"Radiology"},{"key":"13539_CR98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2018.07.016","volume":"54","author":"A Quattrone","year":"2018","unstructured":"Quattrone A, Morelli M, Nigro S, Quattrone A, Vescio B, Arabia G et al (2018) A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson\u2019s disease. Parkinsonism Relat Disord 54:3\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.07.016","journal-title":"Parkinsonism Relat Disord"},{"key":"13539_CR99","doi-asserted-by":"publisher","first-page":"109518","DOI":"10.1016\/j.compbiomed.2024.109518","volume":"185","author":"H Volkmann","year":"2025","unstructured":"Volkmann H, Hoglinger GU, Gron G, Barlescu LA, group D-Ps, Muller HP et al (2025) MRI classification of progressive supranuclear palsy, Parkinson disease and controls using deep learning and machine learning algorithms for the identification of regions and tracts of interest as potential biomarkers. Comput Biol Med 185:109518. https:\/\/doi.org\/10.1016\/j.compbiomed.2024.109518","journal-title":"Comput Biol Med"},{"issue":"3","key":"13539_CR100","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0720-048X(03)00214-6","volume":"51","author":"R Juh","year":"2004","unstructured":"Juh R, Kim J, Moon D, Choe B, Suh T (2004) Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 51(3):223\u2013233. https:\/\/doi.org\/10.1016\/S0720-048X(03)00214-6","journal-title":"Eur J Radiol"},{"issue":"3","key":"13539_CR101","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.neuroimage.2005.03.012","volume":"26","author":"T Eckert","year":"2005","unstructured":"Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS et al (2005) FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26(3):912\u2013921. https:\/\/doi.org\/10.1016\/j.neuroimage.2005.03.012","journal-title":"Neuroimage"},{"key":"13539_CR102","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fneur.2018.00483","volume":"9","author":"L Beyer","year":"2018","unstructured":"Beyer L, Meyer-Wilmes J, Schonecker S, Schnabel J, Brendel E, Prix C et al (2018) Clinical routine FDG-PET imaging of suspected progressive supranuclear palsy and corticobasal degeneration: a gatekeeper for subsequent tau-PET imaging? Front Neurol 9:483. https:\/\/doi.org\/10.3389\/fneur.2018.00483","journal-title":"Front Neurol"},{"issue":"18","key":"13539_CR103","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1021\/acschemneuro.3c00437","volume":"14","author":"J Li","year":"2023","unstructured":"Li J, Kumar A, Langstrom B, Nordberg A, Agren H (2023) Insight into the binding of first- and second-generation PET tracers to 4R and 3R\/4R tau protofibrils. ACS Chem Neurosci 14(18):3528\u20133539. https:\/\/doi.org\/10.1021\/acschemneuro.3c00437","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"13539_CR104","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M et al (2020) Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol 77(11):1408\u20131419. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2526","journal-title":"JAMA Neurol"},{"issue":"1","key":"13539_CR105","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/mds.26834","volume":"32","author":"JL Whitwell","year":"2017","unstructured":"Whitwell JL, Lowe VJ, Tosakulwong N, Weigand SD, Senjem ML, Schwarz CG et al (2017) [(18) F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord 32(1):124\u2013133. https:\/\/doi.org\/10.1002\/mds.26834","journal-title":"Mov Disord"},{"key":"13539_CR106","doi-asserted-by":"publisher","first-page":"105226","DOI":"10.1016\/j.parkreldis.2022.11.018","volume":"106","author":"K Oliveira Hauer","year":"2023","unstructured":"Oliveira Hauer K, Pawlik D, Leuzy A, Janelidze S, Hall S, Hansson O et al (2023) Performance of [(18)F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy. Parkinsonism Relat Disord 106:105226. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.11.018","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"13539_CR107","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/ene.13164","volume":"24","author":"A Ishiki","year":"2017","unstructured":"Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL et al (2017) Tau imaging with [(18) F]THK-5351 in progressive supranuclear palsy. Eur J Neurol 24(1):130\u2013136. https:\/\/doi.org\/10.1111\/ene.13164","journal-title":"Eur J Neurol"},{"issue":"22","key":"13539_CR108","doi-asserted-by":"publisher","first-page":"e1989","DOI":"10.1212\/WNL.0000000000005610","volume":"90","author":"L Passamonti","year":"2018","unstructured":"Passamonti L, Rodriguez PV, Hong YT, Allinson KSJ, Bevan-Jones WR, Williamson D et al (2018) [(11)C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. Neurology 90(22):e1989\u2013e1996. https:\/\/doi.org\/10.1212\/WNL.0000000000005610","journal-title":"Neurology"},{"issue":"7","key":"13539_CR109","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jnnp-2020-325549","volume":"92","author":"M Malpetti","year":"2021","unstructured":"Malpetti M, Passamonti L, Jones PS, Street D, Rittman T, Fryer TD et al (2021) Neuroinflammation predicts disease progression in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 92(7):769\u2013775. https:\/\/doi.org\/10.1136\/jnnp-2020-325549","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"13539_CR110","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/ana.25911","volume":"88","author":"M Malpetti","year":"2020","unstructured":"Malpetti M, Passamonti L, Rittman T, Jones PS, Vazquez Rodriguez P, Bevan-Jones WR et al (2020) Neuroinflammation and tau colocalize in vivo in progressive supranuclear palsy. Ann Neurol 88(6):1194\u20131204. https:\/\/doi.org\/10.1002\/ana.25911","journal-title":"Ann Neurol"},{"issue":"1","key":"13539_CR111","doi-asserted-by":"publisher","first-page":"15761","DOI":"10.1038\/s41598-020-72321-y","volume":"10","author":"T Shigekiyo","year":"2020","unstructured":"Shigekiyo T, Arawaka S (2020) Laterality of specific binding ratios on DAT-SPECT for differential diagnosis of degenerative parkinsonian syndromes. Sci Rep 10(1):15761. https:\/\/doi.org\/10.1038\/s41598-020-72321-y","journal-title":"Sci Rep"},{"key":"13539_CR112","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fmed.2019.00090","volume":"6","author":"S Chalon","year":"2019","unstructured":"Chalon S, Vercouillie J, Payoux P, Deloye JB, Malherbe C, Le Jeune F et al (2019) The story of the dopamine transporter PET tracer LBT-999: from conception to clinical use. Front Med 6:90. https:\/\/doi.org\/10.3389\/fmed.2019.00090","journal-title":"Front Med"},{"key":"13539_CR113","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fneur.2020.00754","volume":"11","author":"MJ Ribeiro","year":"2020","unstructured":"Ribeiro MJ, Vercouillie J, Arlicot N, Tauber C, Gissot V, Mondon K et al (2020) Usefulness of PET with [(18)F]LBT-999 for the evaluation of presynaptic dopaminergic neuronal loss in a clinical environment. Front Neurol 11:754. https:\/\/doi.org\/10.3389\/fneur.2020.00754","journal-title":"Front Neurol"},{"issue":"2","key":"13539_CR114","first-page":"259","volume":"42","author":"AM Catafau","year":"2001","unstructured":"Catafau AM (2001) Brain SPECT in clinical practice. Part I: perfusion. J Nucl Med 42(2):259\u2013271","journal-title":"J Nucl Med"},{"issue":"11","key":"13539_CR115","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s11604-024-01612-5","volume":"42","author":"T Imokawa","year":"2024","unstructured":"Imokawa T, Yokoyama K, Takahashi K, Oyama J, Tsuchiya J, Sanjo N et al (2024) Brain perfusion SPECT in dementia: what radiologists should know. Jpn J Radiol 42(11):1215\u20131230. https:\/\/doi.org\/10.1007\/s11604-024-01612-5","journal-title":"Jpn J Radiol"},{"key":"13539_CR116","doi-asserted-by":"publisher","first-page":"629442","DOI":"10.3389\/fneur.2021.629442","volume":"12","author":"R Ferrando","year":"2021","unstructured":"Ferrando R, Damian A (2021) Brain SPECT as a biomarker of neurodegeneration in dementia in the era of molecular imaging: still a valid option? Front Neurol 12:629442. https:\/\/doi.org\/10.3389\/fneur.2021.629442","journal-title":"Front Neurol"},{"issue":"5","key":"13539_CR117","first-page":"704","volume":"33","author":"KA Johnson","year":"1992","unstructured":"Johnson KA, Sperling RA, Holman BL, Nagel JS, Growdon JH (1992) Cerebral perfusion in progressive supranuclear palsy. J Nucl Med 33(5):704\u2013709","journal-title":"J Nucl Med"},{"issue":"12","key":"13539_CR118","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3174\/ajnr.A8313","volume":"45","author":"G Keir","year":"2024","unstructured":"Keir G, Roytman M, Mashriqi F, Shahsavarani S, Franceschi AM (2024) Atypical parkinsonian syndromes: structural, functional, and molecular imaging features. AJNR Am J Neuroradiol 45(12):1865\u20131877. https:\/\/doi.org\/10.3174\/ajnr.A8313","journal-title":"AJNR Am J Neuroradiol"},{"key":"13539_CR119","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.parkreldis.2018.12.008","volume":"62","author":"G Barbagallo","year":"2019","unstructured":"Barbagallo G, Morelli M, Quattrone A, Chiriaco C, Vaccaro MG, Gulla D et al (2019) In vivo evidence for decreased scyllo-inositol levels in the supplementary motor area of patients with Progressive Supranuclear Palsy: a proton MR spectroscopy study. Parkinsonism Relat Disord 62:185\u2013191. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.12.008","journal-title":"Parkinsonism Relat Disord"},{"key":"13539_CR120","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.nbd.2015.05.020","volume":"82","author":"M Jin","year":"2015","unstructured":"Jin M, Selkoe DJ (2015) Systematic analysis of time-dependent neural effects of soluble amyloid beta oligomers in culture and in vivo: prevention by scyllo-inositol. Neurobiol Dis 82:152\u2013163. https:\/\/doi.org\/10.1016\/j.nbd.2015.05.020","journal-title":"Neurobiol Dis"},{"issue":"2","key":"13539_CR121","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000490349","volume":"65","author":"H Benveniste","year":"2019","unstructured":"Benveniste H, Liu X, Koundal S, Sanggaard S, Lee H, Wardlaw J (2019) The glymphatic system and waste clearance with brain aging: a review. Gerontology 65(2):106\u2013119. https:\/\/doi.org\/10.1159\/000490349","journal-title":"Gerontology"},{"issue":"12","key":"13539_CR122","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1007\/s11064-015-1581-6","volume":"40","author":"NA Jessen","year":"2015","unstructured":"Jessen NA, Munk AS, Lundgaard I, Nedergaard M (2015) The glymphatic system: a beginner\u2019s guide. Neurochem Res 40(12):2583\u20132599. https:\/\/doi.org\/10.1007\/s11064-015-1581-6","journal-title":"Neurochem Res"},{"key":"13539_CR123","doi-asserted-by":"publisher","DOI":"10.1159\/000530075","author":"M Ota","year":"2023","unstructured":"Ota M, Sato N, Takahashi Y, Shigemoto Y, Kimura Y, Nakaya M et al (2023) Correlation between the regional brain volume and glymphatic system activity in progressive supranuclear palsy. Dement Geriatr Cogn Disord. https:\/\/doi.org\/10.1159\/000530075","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"13539_CR124","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41531-022-00437-1","volume":"8","author":"T Shen","year":"2022","unstructured":"Shen T, Yue Y, Ba F, He T, Tang X, Hu X et al (2022) Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson\u2019s disease. NPJ Parkinsons Dis 8(1):174. https:\/\/doi.org\/10.1038\/s41531-022-00437-1","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"13539_CR125","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s11604-023-01454-7","volume":"41","author":"Y Saito","year":"2023","unstructured":"Saito Y, Kamagata K, Andica C, Uchida W, Takabayashi K, Yoshida S et al (2023) Glymphatic system impairment in corticobasal syndrome: diffusion tensor image analysis along the perivascular space (DTI-ALPS). Jpn J Radiol 41(11):1226\u20131235. https:\/\/doi.org\/10.1007\/s11604-023-01454-7","journal-title":"Jpn J Radiol"},{"issue":"1","key":"13539_CR126","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ana.26516","volume":"93","author":"JL Hsu","year":"2023","unstructured":"Hsu JL, Wei YC, Toh CH, Hsiao IT, Lin KJ, Yen TC et al (2023) Magnetic resonance images implicate that glymphatic alterations mediate cognitive dysfunction in Alzheimer disease. Ann Neurol 93(1):164\u2013174. https:\/\/doi.org\/10.1002\/ana.26516","journal-title":"Ann Neurol"},{"issue":"5","key":"13539_CR127","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/RLU.0000000000005141","volume":"49","author":"JL Hsu","year":"2024","unstructured":"Hsu JL, Wei YC, Hsiao IT, Lin KJ, Yen TC, Lu CS et al (2024) Dominance of tau burden in cortical over subcortical regions mediates glymphatic activity and clinical severity in PSP. Clin Nucl Med 49(5):387\u2013396. https:\/\/doi.org\/10.1097\/RLU.0000000000005141","journal-title":"Clin Nucl Med"},{"issue":"2","key":"13539_CR128","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00234-023-03270-2","volume":"66","author":"G Ringstad","year":"2024","unstructured":"Ringstad G (2024) Glymphatic imaging: a critical look at the DTI-ALPS index. Neuroradiology 66(2):157\u2013160. https:\/\/doi.org\/10.1007\/s00234-023-03270-2","journal-title":"Neuroradiology"},{"issue":"4","key":"13539_CR129","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11604-017-0617-z","volume":"35","author":"T Taoka","year":"2017","unstructured":"Taoka T, Masutani Y, Kawai H, Nakane T, Matsuoka K, Yasuno F et al (2017) Evaluation of glymphatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer\u2019s disease cases. Jpn J Radiol 35(4):172\u2013178. https:\/\/doi.org\/10.1007\/s11604-017-0617-z","journal-title":"Jpn J Radiol"},{"issue":"5","key":"13539_CR130","doi-asserted-by":"publisher","first-page":"e70434","DOI":"10.1111\/cns.70434","volume":"31","author":"K Shirbandi","year":"2025","unstructured":"Shirbandi K, Jafari M, Mazaheri F, Tahmasbi M (2025) Diffusion tensor imaging along the perivascular space is a promising imaging method in Parkinson\u2019s disease: a systematic review and meta-analysis study. CNS Neurosci Ther 31(5):e70434. https:\/\/doi.org\/10.1111\/cns.70434","journal-title":"CNS Neurosci Ther"},{"issue":"Pt 2","key":"13539_CR131","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/brain\/awv361","volume":"139","author":"PJ Planetta","year":"2016","unstructured":"Planetta PJ, Ofori E, Pasternak O, Burciu RG, Shukla P, DeSimone JC et al (2016) Free-water imaging in Parkinson\u2019s disease and atypical parkinsonism. Brain 139(Pt 2):495\u2013508. https:\/\/doi.org\/10.1093\/brain\/awv361","journal-title":"Brain"},{"issue":"4","key":"13539_CR132","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.neuroimage.2012.03.072","volume":"61","author":"H Zhang","year":"2012","unstructured":"Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC (2012) NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 61(4):1000\u20131016. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.03.072","journal-title":"Neuroimage"},{"issue":"17","key":"13539_CR133","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1002\/hbm.24760","volume":"40","author":"T Mitchell","year":"2019","unstructured":"Mitchell T, Archer DB, Chu WT, Coombes SA, Lai S, Wilkes BJ et al (2019) Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp 40(17):5094\u20135107. https:\/\/doi.org\/10.1002\/hbm.24760","journal-title":"Hum Brain Mapp"},{"key":"13539_CR134","doi-asserted-by":"publisher","first-page":"118417","DOI":"10.1016\/j.neuroimage.2021.118417","volume":"241","author":"T Dhollander","year":"2021","unstructured":"Dhollander T, Clemente A, Singh M, Boonstra F, Civier O, Duque JD et al (2021) Fixel-based analysis of diffusion MRI: methods, applications, challenges and opportunities. Neuroimage 241:118417. https:\/\/doi.org\/10.1016\/j.neuroimage.2021.118417","journal-title":"Neuroimage"},{"key":"13539_CR135","doi-asserted-by":"publisher","first-page":"103022","DOI":"10.1016\/j.nicl.2022.103022","volume":"34","author":"T Mitchell","year":"2022","unstructured":"Mitchell T, Wilkes BJ, Archer DB, Chu WT, Coombes SA, Lai S et al (2022) Advanced diffusion imaging to track progression in Parkinson\u2019s disease, multiple system atrophy, and progressive supranuclear palsy. Neuroimage Clin 34:103022. https:\/\/doi.org\/10.1016\/j.nicl.2022.103022","journal-title":"Neuroimage Clin"},{"key":"13539_CR136","doi-asserted-by":"publisher","first-page":"625874","DOI":"10.3389\/fnagi.2021.625874","volume":"13","author":"TT Nguyen","year":"2021","unstructured":"Nguyen TT, Cheng JS, Chen YL, Lin YC, Tsai CC, Lu CS et al (2021) Fixel-based analysis of white matter degeneration in patients with progressive supranuclear palsy or multiple system atrophy, as compared to Parkinson\u2019s disease. Front Aging Neurosci 13:625874. https:\/\/doi.org\/10.3389\/fnagi.2021.625874","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"13539_CR137","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41531-023-00565-2","volume":"9","author":"W Uchida","year":"2023","unstructured":"Uchida W, Kamagata K, Andica C, Takabayashi K, Saito Y, Owaki M et al (2023) Fiber-specific micro- and macroscopic white matter alterations in progressive supranuclear palsy and corticobasal syndrome. NPJ Parkinsons Dis 9(1):122. https:\/\/doi.org\/10.1038\/s41531-023-00565-2","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"13539_CR138","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1073\/pnas.1807983116","volume":"116","author":"CM Cassidy","year":"2019","unstructured":"Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME et al (2019) Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci U S A 116(11):5108\u20135117. https:\/\/doi.org\/10.1073\/pnas.1807983116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"13539_CR139","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/mds.27365","volume":"33","author":"D Taniguchi","year":"2018","unstructured":"Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A et al (2018) Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson\u2019s disease. Mov Disord 33(9):1488\u20131492. https:\/\/doi.org\/10.1002\/mds.27365","journal-title":"Mov Disord"},{"issue":"1","key":"13539_CR140","doi-asserted-by":"publisher","first-page":"fcaf022","DOI":"10.1093\/braincomms\/fcaf022","volume":"7","author":"C Marotta","year":"2025","unstructured":"Marotta C, Sinclair B, O\u2019Brien TJ, Vivash L (2025) Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials. Brain Commun 7(1):fcaf022. https:\/\/doi.org\/10.1093\/braincomms\/fcaf022","journal-title":"Brain Commun"},{"key":"13539_CR141","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.parkreldis.2017.03.008","volume":"39","author":"N Upadhyay","year":"2017","unstructured":"Upadhyay N, Suppa A, Piattella MC, Gianni C, Bologna M, Di Stasio F et al (2017) Functional disconnection of thalamic and cerebellar dentate nucleus networks in progressive supranuclear palsy and corticobasal syndrome. Parkinsonism Relat Disord 39:52\u201357. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.03.008","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"13539_CR142","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.parkreldis.2011.05.013","volume":"17","author":"JL Whitwell","year":"2011","unstructured":"Whitwell JL, Avula R, Master A, Vemuri P, Senjem ML, Jones DT et al (2011) Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. Parkinsonism Relat Disord 17(8):599\u2013605. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.05.013","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"13539_CR143","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ana.23844","volume":"73","author":"RC Gardner","year":"2013","unstructured":"Gardner RC, Boxer AL, Trujillo A, Mirsky JB, Guo CC, Gennatas ED et al (2013) Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol 73(5):603\u2013616. https:\/\/doi.org\/10.1002\/ana.23844","journal-title":"Ann Neurol"},{"issue":"5","key":"13539_CR144","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3174\/ajnr.A4229","volume":"36","author":"MC Piattella","year":"2015","unstructured":"Piattella MC, Tona F, Bologna M, Sbardella E, Formica A, Petsas N et al (2015) Disrupted resting-state functional connectivity in progressive supranuclear palsy. AJNR Am J Neuroradiol 36(5):915\u2013921. https:\/\/doi.org\/10.3174\/ajnr.A4229","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"13539_CR145","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.27546","volume":"34","author":"JL Whitwell","year":"2019","unstructured":"Whitwell JL, Tosakulwong N, Schwarz CG, Botha H, Senjem ML, Spychalla AJ et al (2019) MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy. Mov Disord 34(1):105\u2013113. https:\/\/doi.org\/10.1002\/mds.27546","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"13539_CR146","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/infdis\/jiac370","volume":"227","author":"SB Joseph","year":"2023","unstructured":"Joseph SB, Gianella S, Burdo TH, Cinque P, Gisslen M, Letendre S et al (2023) Biotypes of central nervous system complications in people with human immunodeficiency virus: virology, immunology, and neuropathology. J Infect Dis 227(Suppl 1):S3\u2013S15. https:\/\/doi.org\/10.1093\/infdis\/jiac370","journal-title":"J Infect Dis"},{"issue":"10","key":"13539_CR147","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0000000000009058","volume":"94","author":"D Ferreira","year":"2020","unstructured":"Ferreira D, Nordberg A, Westman E (2020) Biological subtypes of Alzheimer disease: a systematic review and meta-analysis. Neurology 94(10):436\u2013448. https:\/\/doi.org\/10.1212\/WNL.0000000000009058","journal-title":"Neurology"},{"issue":"11","key":"13539_CR148","doi-asserted-by":"publisher","first-page":"e1445","DOI":"10.1212\/WNL.0000000000010498","volume":"95","author":"L Wang","year":"2020","unstructured":"Wang L, Cheng W, Rolls ET, Dai F, Gong W, Du J et al (2020) Association of specific biotypes in patients with Parkinson disease and disease progression. Neurology 95(11):e1445\u2013e1460. https:\/\/doi.org\/10.1212\/WNL.0000000000010498","journal-title":"Neurology"},{"issue":"2","key":"13539_CR149","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/acn3.51974","volume":"11","author":"N Samudra","year":"2024","unstructured":"Samudra N, Lerner H, Yack L, Walsh CM, Kirsch HE, Kudo K et al (2024) Spatiotemporal characteristics of neurophysiological changes in patients with four-repeat tauopathies. Ann Clin Transl Neurol 11(2):525\u2013535. https:\/\/doi.org\/10.1002\/acn3.51974","journal-title":"Ann Clin Transl Neurol"},{"key":"13539_CR150","doi-asserted-by":"publisher","first-page":"102876","DOI":"10.1016\/j.eclinm.2024.102876","volume":"77","author":"A Feng","year":"2024","unstructured":"Feng A, Zhi D, Feng Y, Jiang R, Fu Z, Xu M et al (2024) Functional imaging derived ADHD biotypes based on deep clustering: a study on personalized medication therapy guidance. EClinMed 77:102876. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102876","journal-title":"EClinMed"},{"issue":"1","key":"13539_CR151","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41398-023-02729-3","volume":"14","author":"I Schnorr","year":"2024","unstructured":"Schnorr I, Siegl A, Luckhardt S, Wenz S, Friedrichsen H, El Jomaa H et al (2024) Inflammatory biotype of ADHD is linked to chronic stress: a data-driven analysis of the inflammatory proteome. Transl Psychiatry 14(1):37. https:\/\/doi.org\/10.1038\/s41398-023-02729-3","journal-title":"Transl Psychiatry"},{"issue":"1","key":"13539_CR152","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/npr2.70010","volume":"45","author":"Y Yasuda","year":"2025","unstructured":"Yasuda Y, Ito S, Matsumoto J, Okada N, Onitsuka T, Ikeda M et al (2025) Proposal for a novel classification of patients with enlarged ventricles and cognitive impairment based on data-driven analysis of neuroimaging results in patients with psychiatric disorders. Neuropsychopharmacol Rep 45(1):e70010. https:\/\/doi.org\/10.1002\/npr2.70010","journal-title":"Neuropsychopharmacol Rep"},{"key":"13539_CR153","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bbr.2012.12.032","volume":"242","author":"RA Kohman","year":"2013","unstructured":"Kohman RA, Bhattacharya TK, Kilby C, Bucko P, Rhodes JS (2013) Effects of minocycline on spatial learning, hippocampal neurogenesis and microglia in aged and adult mice. Behav Brain Res 242:17\u201324. https:\/\/doi.org\/10.1016\/j.bbr.2012.12.032","journal-title":"Behav Brain Res"},{"issue":"2","key":"13539_CR154","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","volume":"77","author":"R Howard","year":"2020","unstructured":"Howard R, Zubko O, Bradley R, Harper E, Pank L, O\u2019Brien J et al (2020) Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial. JAMA Neurol 77(2):164\u2013174. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3762","journal-title":"JAMA Neurol"},{"issue":"4","key":"13539_CR155","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14(4):388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"issue":"12","key":"13539_CR156","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/S1474-4422(19)30333-5","volume":"18","author":"AL Boxer","year":"2019","unstructured":"Boxer AL (2019) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 18(12):1102\u20131111. https:\/\/doi.org\/10.1016\/S1474-4422(19)30333-5","journal-title":"Lancet Neurol"},{"key":"13539_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111663","author":"CM Cristiani","year":"2024","unstructured":"Cristiani CM, Calomino C, Scaramuzzino L, Murfuni MS, Parrotta EI, Bianco MG et al (2024) Proximity elongation assay and ELISA for the identification of serum diagnostic biomarkers in Parkinson\u2019s disease and progressive supranuclear palsy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252111663","journal-title":"Int J Mol Sci"},{"issue":"1","key":"13539_CR158","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13195-020-00728-w","volume":"12","author":"S De Meyer","year":"2020","unstructured":"De Meyer S, Schaeverbeke JM, Verberk IMW, Gille B, De Schaepdryver M, Luckett ES et al (2020) Comparison of ELISA- and SIMOA-based quantification of plasma A\u03b2 ratios for early detection of cerebral amyloidosis. Alzheimers Res Ther 12(1):162. https:\/\/doi.org\/10.1186\/s13195-020-00728-w","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"13539_CR159","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-023-02672-z","volume":"147","author":"C Aguero","year":"2024","unstructured":"Aguero C, Dhaynaut M, Amaral AC, Moon SH, Neelamegam R, Scapellato M et al (2024) Head-to-head comparison of [(18)F]-Flortaucipir, [(18)F]-MK-6240 and [(18)F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases. Acta Neuropathol 147(1):25. https:\/\/doi.org\/10.1007\/s00401-023-02672-z","journal-title":"Acta Neuropathol"},{"issue":"22","key":"13539_CR160","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M et al (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73(22):1914\u20131922. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c47cc2","journal-title":"Neurology"},{"issue":"12","key":"13539_CR161","doi-asserted-by":"publisher","first-page":"8376","DOI":"10.1007\/s12035-019-01676-9","volume":"56","author":"S Herrera-Espejo","year":"2019","unstructured":"Herrera-Espejo S, Santos-Zorrozua B, Alvarez-Gonzalez P, Lopez-Lopez E, Garcia-Orad A (2019) A systematic review of MicroRNA expression as biomarker of late-onset Alzheimer\u2019s disease. Mol Neurobiol 56(12):8376\u20138391. https:\/\/doi.org\/10.1007\/s12035-019-01676-9","journal-title":"Mol Neurobiol"},{"issue":"8","key":"13539_CR162","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E et al (2019) Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry 24(8):1112\u20131134. https:\/\/doi.org\/10.1038\/s41380-018-0342-8","journal-title":"Mol Psychiatry"},{"issue":"5","key":"13539_CR163","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1212\/01.wnl.0000078192.95645.e6","volume":"61","author":"A Gerhard","year":"2003","unstructured":"Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN et al (2003) [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 61(5):686\u2013689. https:\/\/doi.org\/10.1212\/01.wnl.0000078192.95645.e6","journal-title":"Neurology"},{"issue":"2","key":"13539_CR164","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis 21(2):404\u2013412. https:\/\/doi.org\/10.1016\/j.nbd.2005.08.002","journal-title":"Neurobiol Dis"},{"issue":"1","key":"13539_CR165","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/mds.20668","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 21(1):89\u201393. https:\/\/doi.org\/10.1002\/mds.20668","journal-title":"Mov Disord"},{"issue":"10","key":"13539_CR166","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/mds.20162","volume":"19","author":"A Gerhard","year":"2004","unstructured":"Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K et al (2004) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord 19(10):1221\u20131226. https:\/\/doi.org\/10.1002\/mds.20162","journal-title":"Mov Disord"},{"issue":"1","key":"13539_CR167","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ana.26930","volume":"96","author":"I Garcia-Cordero","year":"2024","unstructured":"Garcia-Cordero I, Anastassiadis C, Khoja A, Morales-Rivero A, Thapa S, Vasilevskaya A et al (2024) Evaluating the effect of Alzheimer\u2019s disease-related biomarker change in corticobasal syndrome and progressive supranuclear palsy. Ann Neurol 96(1):99\u2013109. https:\/\/doi.org\/10.1002\/ana.26930","journal-title":"Ann Neurol"},{"issue":"7","key":"13539_CR168","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/brain\/awz122","volume":"142","author":"S Spina","year":"2019","unstructured":"Spina S, Brown JA, Deng J, Gardner RC, Nana AL, Hwang JL et al (2019) Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies. Brain 142(7):2068\u20132081. https:\/\/doi.org\/10.1093\/brain\/awz122","journal-title":"Brain"},{"issue":"7","key":"13539_CR169","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jalz.2017.05.001","volume":"13","author":"MW Weiner","year":"2017","unstructured":"Weiner MW (2017) The Alzheimer\u2019s disease neuroimaging initiative: a review of progress and future directions. Alzheimers Dement 13(7):e1\u2013e24. https:\/\/doi.org\/10.1016\/j.jalz.2017.05.001","journal-title":"Alzheimers Dement"},{"key":"13539_CR170","doi-asserted-by":"publisher","first-page":"102514","DOI":"10.1016\/j.nicl.2020.102514","volume":"28","author":"S Liang","year":"2020","unstructured":"Liang S, Deng W, Li X, Greenshaw AJ, Wang Q, Li M et al (2020) Biotypes of major depressive disorder: neuroimaging evidence from resting-state default mode network patterns. Neuroimage Clin 28:102514. https:\/\/doi.org\/10.1016\/j.nicl.2020.102514","journal-title":"Neuroimage Clin"},{"issue":"1","key":"13539_CR171","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41386-020-00849-8","volume":"46","author":"CA Tamminga","year":"2021","unstructured":"Tamminga CA, Clementz BA, Pearlson G, Keshavan M, Gershon ES, Ivleva EI et al (2021) Biotyping in psychosis: using multiple computational approaches with one data set. Neuropsychopharmacology 46(1):143\u2013155. https:\/\/doi.org\/10.1038\/s41386-020-00849-8","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"13539_CR172","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s11764-020-00863-1","volume":"14","author":"SR Kesler","year":"2020","unstructured":"Kesler SR, Petersen ML, Rao V, Harrison RA, Palesh O (2020) Functional connectome biotypes of chemotherapy-related cognitive impairment. J Cancer Surviv 14(4):483\u2013493. https:\/\/doi.org\/10.1007\/s11764-020-00863-1","journal-title":"J Cancer Surviv"},{"key":"13539_CR173","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jad.2023.02.118","volume":"329","author":"X Chen","year":"2023","unstructured":"Chen X, Dai Z, Lin Y (2023) Biotypes of major depressive disorder identified by a multiview clustering framework. J Affect Disord 329:257\u2013272. https:\/\/doi.org\/10.1016\/j.jad.2023.02.118","journal-title":"J Affect Disord"},{"issue":"6","key":"13539_CR174","doi-asserted-by":"publisher","first-page":"e2318411","DOI":"10.1001\/jamanetworkopen.2023.18411","volume":"6","author":"LM Hack","year":"2023","unstructured":"Hack LM, Tozzi L, Zenteno S, Olmsted AM, Hilton R, Jubeir J et al (2023) A cognitive biotype of depression and symptoms, behavior measures, neural circuits, and differential treatment outcomes: a prespecified secondary analysis of a randomized clinical trial. JAMA Netw Open 6(6):e2318411. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.18411","journal-title":"JAMA Netw Open"},{"issue":"5","key":"13539_CR175","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/02664760902729641","volume":"37","author":"MI Rolfe","year":"2010","unstructured":"Rolfe MI, Mengersen K, Beadle G, Vearncombe K, Andrew B, Johnson HL et al (2010) Latent class piecewise linear trajectory modelling for short-term cognition responses after chemotherapy for breast cancer patients. J Appl Stat 37(5):725\u2013738. https:\/\/doi.org\/10.1080\/02664760902729641","journal-title":"J Appl Stat"},{"issue":"3","key":"13539_CR176","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s11764-022-01310-z","volume":"18","author":"JA Agelink van Rentergem","year":"2024","unstructured":"Agelink van Rentergem JA, Lee Meeuw Kjoe PR, Vermeulen IE, Schagen SB (2024) Subgroups of cognitively affected and unaffected breast cancer survivors after chemotherapy: a data-driven approach. J Cancer Surviv 18(3):810\u2013817. https:\/\/doi.org\/10.1007\/s11764-022-01310-z","journal-title":"J Cancer Surviv"},{"issue":"1","key":"13539_CR177","doi-asserted-by":"publisher","first-page":"12980","DOI":"10.1038\/s41598-023-38101-0","volume":"13","author":"JD Koen","year":"2023","unstructured":"Koen JD, Lewis L, Rugg MD, Clementz BA, Keshavan MS, Pearlson GD et al (2023) Supervised machine learning classification of psychosis biotypes based on brain structure: findings from the Bipolar-Schizophrenia network for intermediate phenotypes (B-SNIP). Sci Rep 13(1):12980. https:\/\/doi.org\/10.1038\/s41598-023-38101-0","journal-title":"Sci Rep"},{"issue":"8","key":"13539_CR178","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/mds.27666","volume":"34","author":"MJ Grimm","year":"2019","unstructured":"Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E et al (2019) How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord 34(8):1228\u20131232. https:\/\/doi.org\/10.1002\/mds.27666","journal-title":"Mov Disord"},{"issue":"7","key":"13539_CR179","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/jnnp-2018-320151","volume":"90","author":"E Jabbari","year":"2019","unstructured":"Jabbari E, Woodside J, Guo T, Magdalinou NK, Chelban V, Athauda D et al (2019) Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 90(7):768\u2013773. https:\/\/doi.org\/10.1136\/jnnp-2018-320151","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13539-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13539-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13539-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:58:21Z","timestamp":1773665901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13539-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":179,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["13539"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13539-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"29"}}